Mast Therapeutics - Articles and news items

Mast Therapeutics initiates Phase 3 extension study of vepoloxamer in sickle cell disease

Industry news / 26 May 2015 / Victoria White

Mast Therapeutics has initiated an open-label, multicentre Phase 3 extension study of vepoloxamer (MST-188) in sickle cell disease, referred to as “EPIC-E”…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+